Randomized clinical trials in favorable prognosis stage I-II Hodgkin's lymphoma.
| Group . | Treatment arms . | n . | FFS . | OS . | Time (y) . |
|---|---|---|---|---|---|
| Abbreviations: FFS, failure-free survival; OS, overall survival; VBM, vinblastine, bleomycin, methotrexate; IFRT, involved field radiotherapy; EORTC, European Organization for Reserach and Treatment of Cancer; EBVP, epirubicin, bleomycin, vinblastine, prednisone; STLI, sub-total lymphoid irradiaton; MSKCC, Memorial Sloan-Kettering Cancer Center; TBV, thiotepa, bleomycin, methotrexate; MOPP, nitrogen mustard, vincristine, procarbazine, prednisone | |||||
| Stanford | VBM × 6 + IFRT 36 Gy | 35 | 88% | 94% | 5 |
| STLI 30-40-44 Gy | 43 | 93% | 98% | ||
| p=0.60 | p=0.50 | ||||
| EORTC H7F | EBVP × 6 + IFRT 36 Gy | 168 | 92% | 98% | 6 |
| STLI 36-40 Gy | 165 | 81% | 96% | ||
| p=0.004 | p=0.156 | ||||
| MSKCC | TBV × 4 + mantle field | 59 | 81% | 91% | 5 |
| MOPP × 4 + mantle field | 61 | 89% | 91% | ||
| p=0.23 | p=0.83 | ||||
| Group . | Treatment arms . | n . | FFS . | OS . | Time (y) . |
|---|---|---|---|---|---|
| Abbreviations: FFS, failure-free survival; OS, overall survival; VBM, vinblastine, bleomycin, methotrexate; IFRT, involved field radiotherapy; EORTC, European Organization for Reserach and Treatment of Cancer; EBVP, epirubicin, bleomycin, vinblastine, prednisone; STLI, sub-total lymphoid irradiaton; MSKCC, Memorial Sloan-Kettering Cancer Center; TBV, thiotepa, bleomycin, methotrexate; MOPP, nitrogen mustard, vincristine, procarbazine, prednisone | |||||
| Stanford | VBM × 6 + IFRT 36 Gy | 35 | 88% | 94% | 5 |
| STLI 30-40-44 Gy | 43 | 93% | 98% | ||
| p=0.60 | p=0.50 | ||||
| EORTC H7F | EBVP × 6 + IFRT 36 Gy | 168 | 92% | 98% | 6 |
| STLI 36-40 Gy | 165 | 81% | 96% | ||
| p=0.004 | p=0.156 | ||||
| MSKCC | TBV × 4 + mantle field | 59 | 81% | 91% | 5 |
| MOPP × 4 + mantle field | 61 | 89% | 91% | ||
| p=0.23 | p=0.83 | ||||